Stay updated with breaking news from Bushra sayed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Updated: Share Article AAA The Bombay High Court on Thursday refused to hear a public interest litigation (PIL) petition seeking to quash the different rates of COVID-19 vaccines by Serum Institute of India (SII) and Bharat Biotech for the Centre and State governments and fix the price at ₹150 per dose. A Division Bench of Chief Justice Dipankar Datta and Justice G.S. Kulkarni said, “The Supreme Court has said that issues that have pan-India effect will be dealt with by it and pricing is a phenomenon applicable all over India. We are not entertaining it (PIL) as the apex court has fairly covered it.” ....
MUMBAI: Let there be uniform Covid-19 vaccine rates, a public interest litigation has urged the Bombay High Court challenging the intelligible different rates of Covishield and Covaxin by pharmaceutical companies for sale to government and private hospitals. The PIL is filed by advocate Fayzan Khan and three law students - Arman Parve, Bushra Sayed and Trupti Gaikar - who are aggrieved at the varying charges announced by Serum Institute of India for its vaccine Covidshield at Rs 400/- for State government and Rs 600/- for private hospitals. Similarly Bharat Biotech also announced per dose Covaxin rates at Rs 600 for State government, Rs 1200 to private hospitals and $ 15-20 for exports. The petition has referred to media reports and annexed a comparative chart that shows that the vaccine is much cheaper in foreign countries. “This denotes that the pharma companies are milking the fear psychosis of increased death rates due to Covid19,’’ says the PIL filed through a ....